Scarica l'app Stockscreener
1.54
5.25%
-0.08
Dopo l'orario di chiusura:
1.58
0.04
+2.60%
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences’ (NERV) Neutral Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences stock hits 52-week low at $1.7 By Investing.com - Investing.com Australia
Investor Network: Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences stock hits 52-week low at $1.7 - Investing.com
Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences: Q4 Earnings Snapshot - CTPost
Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints - TipRanks
Minerva Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Minerva Neurosciences: Q4 Earnings Snapshot -February 25, 2025 at 07:33 am EST - Marketscreener.com
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - The Manila Times
From $30M Loss to Profit: How Minerva Turned Finances Around While Navigating FDA Hurdles - StockTitan
Minerva Neurosciences, Inc. SEC 10-K Report - TradingView
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Minerva Neurosciences stock hits 52-week low at $1.86 - Investing.com India
Minerva Neurosciences Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Minerva Neurosciences Stock Hits 52-Week Low at $2.03 - MSN
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences stock hits 52-week low at $2.02 By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.02 - Investing.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Armenian Reporter
GHP Investment Advisors Inc. Reduces Stock Holdings in Silgan Holdings Inc. (NYSE:SLGN) - Armenian Reporter
Mohawk Industries (NYSE:MHK) Issues Quarterly Earnings Results - Armenian Reporter
Promising Penny Stocks To Follow Today – February 04th - Armenian Reporter
Chronic Insomnia Market Outlook: Strong Growth Projected by 2032, Highlights DelveInsight - NEWSnet
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
Minerva Neurosciences Faces Listing Compliance Challenges as Nasdaq Grants Continued Listing Subject to ConditionsMinerva Neurosciences Inc. recently encountered challenges regarding its listing on The Nasdaq Capital Market as disclosed in a Form 8 - Defense World
Minerva Neurosciences secures Nasdaq listing extension By Investing.com - Investing.com South Africa
Minerva Neurosciences secures Nasdaq listing extension - Investing.com
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Future Industry Growth Of Cognitive Behavioral Therapy - openPR
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Minerva Neurosciences reports voting results from annual meeting By Investing.com - Investing.com Nigeria
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):